CNS Healthcare Participating in Largest-Ever Global Autism Clinical Trial

Oct. 30, 2012 - PRLog -- According to researchers at CNS Healthcare the ConnectMe clinical research program is currently recruiting children aged six to twelve in local area with autism, Asperger's Disorder, and PDD-NOs, to evaluate the safety, efficacy and tolerabJllty of an investigational drug on two of the core symptoms of these disorders, social interaction and communication skills. The third core symptom of autism spectrum disorders Is restricted interests, repetitive behaviors, and stereotyped mannerisms.

Known for their research in the area of autism, CNS Healthcare researchers said that the research may help reveal valuable insights for the management of autism spectrum disorders, which now affects one in 88 children in the United States according to the Centers for Disease Control and Prevention (CDC).

"This is an exciting trial because there are currently no FDA-approved drugs to treat any of the core symptoms of these autism spectrum disorders," said Dr. Nandita Joshi. "Autism spectrum disorders impact so many members of our community and more research is still needed, which is why CNS Healthcare felt it was so important be a part of this study."

The prevalence of autism spectrum disorders has been increasing rapidly across the United States. A 2008 survey from the CDC found that the prevalence of autism spectrum disorders in the United States has increased by 23% since 2006 and 78 percent since 2002.

Dr. Joshi added that those interested in more information about the ConnectMe clinical research program should call their local office of CNS Healthcare (Orlando, FL at 407-425-5100; Jacksonville, FL at 904-281-5757 or Memphis, TN at 901-843-1045).